Novavax Inc
NASDAQ: NVAX
$8.75
-$0.57 (-6.1%)
Closing Price on November 26, 2024
NVAX Articles
Novavax, Inc. (NASDAQ: NVAX) reported third-quarter financial results after markets closed on Wednesday. The company said that it had a net loss of $0.24 per share and $3.2 million in revenue, versus...
Published:
Last Updated:
Novavax is scheduled to report its third-quarter financial results before the markets open on Wednesday.
Published:
Last Updated:
24/7 Wall St. has put together a preview of Disney, Petrobras and some of the other major companies reporting their quarterly results this week.
Published:
Last Updated:
Frontier Communications remained the most shorted stock traded on the Nasdaq between the September 30 and October 14 settlement dates.
Published:
Last Updated:
Short sellers retreated from Sirius XM just enough between the September 15 and September 30 settlement dates for it to slip out of the top spot on the list of the most shorted stocks traded on the...
Published:
Last Updated:
Corporations forbid employees from buying or selling company shares around the release of earnings for obvious reasons. Things may be ready to quiet down in October.
Published:
Last Updated:
The return of volatility to the markets after the doldrums of August appears to have pointed short sellers at rival chipmakers Intel and AMD.
Published:
Last Updated:
The sell-offs that hit earlier in the month got some insiders interested in shares, and like the week before, they were out again in force last week.
Published:
Last Updated:
24/7 Wall Street has picked out a few companies posting the largest losses for the week, including Novavax and VimpelCom.
Published:
Last Updated:
Novavax was pummeled by shareholders on Friday after the company reported top-line results from its RSV F Vaccine trials.
Published:
Last Updated:
Friday's top analyst upgrades and downgrades include Citigroup, Enterprise Products Partners, GoPro, Lululemon Athletica and Novavax.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in late-September and October.
Published:
Last Updated:
The short interest moves in the most shorted stocks traded on the Nasdaq were mixed between the August 15 and August 31 settlement dates. But short sellers clearly had a couple of favorites.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in September.
Published:
Last Updated:
Short sellers made very few big moves between the July 29 and August 15 settlement dates, at least when it comes to the most shorted stocks traded on the Nasdaq.
Published:
Last Updated: